{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:34:30Z","timestamp":1793957670442,"version":"4.8.0"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["20023"],"award-info":[{"award-number":["20023"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.critrevonc.2024.104307","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T06:16:12Z","timestamp":1708668972000},"page":"104307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Patients\u2019 selection and trial matching in early-phase oncology clinical trials"],"prefix":"10.1016","volume":"196","author":[{"given":"P.","family":"Corbaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Besle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vinceneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Vanacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ouali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hanvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Terret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Verlingue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2024.104307_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41698-023-00487-5","article-title":"Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place","volume":"7","author":"Adashek","year":"2023","journal-title":"NPJ Precis Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104307_bib2","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/ijc.33409","article-title":"Improving patient selection for immuno-oncology phase 1 trials: external validation of six prognostic scores in a French cancer center","volume":"148","author":"Al Darazi","year":"2021","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104307_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2023.04.006","article-title":"Profile and outcome of cancer patients enrolled in contemporary phase I trials","volume":"188","author":"Alouani","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104307_bib4","unstructured":"American Society of Clinical Oncology, 2023. Targeted Agent and Profiling Utilization Registry (TAPUR) Study [Internet]. clinicaltrials.gov [cited May 25, 2023]. Report No.: NCT02693535. Available at: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02693535\u3009."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104307_bib5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.bjc.6604218","article-title":"Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience","volume":"98","author":"Arkenau","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2024.104307_bib6","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2008.19.5081","article-title":"Prospective validation of a prognostic score to improve patient selection for oncology phase I trials","volume":"27","author":"Arkenau","year":"2009","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104307_bib7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.annonc.2022.04.071","article-title":"Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study","volume":"33","author":"Bakouny","year":"2022","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104307_bib8","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ccell.2021.06.010","article-title":"Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic","volume":"39","author":"Bayle","year":"2021","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104307_bib9","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104307_bib10","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.annonc.2020.07.013","article-title":"An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort","volume":"31","author":"Becker","year":"2020","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.04.019","article-title":"Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience","volume":"98","author":"Besle","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104307_bib12","first-page":"139","article-title":"M\u00e9decine de pr\u00e9cision et in\u00e9galit\u00e9s sociales d\u2019acc\u00e8s aux essais pr\u00e9coces en canc\u00e9rologie","author":"Besle","year":"2021","journal-title":"Rev. Fr. Aff. Soc."},{"key":"10.1016\/j.critrevonc.2024.104307_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejca.2017.07.027","article-title":"Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy immune score (GRIm-Score)","volume":"84","author":"Bigot","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104307_bib14","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1740774517710250","article-title":"Experiences of establishing an academic early phase clinical trials unit","volume":"14","author":"Brown","year":"2017","journal-title":"Clin. Trials"},{"key":"10.1016\/j.critrevonc.2024.104307_bib15","unstructured":"Canadian Cancer Trials Group, 2023. Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial [Internet]. clinicaltrials.gov [cited May 25, 2023]. Report No.: NCT03297606. Available at: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03297606\u3009."},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104307_bib16","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1056\/NEJMc1803837","article-title":"Encouraging trends in modern phase 1 oncology trials","volume":"378","author":"Chakiba","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104307_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101610","article-title":"Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study","author":"Charton","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2024.104307_bib18","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/1471-2407-11-426","article-title":"Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?","volume":"11","author":"Chau","year":"2011","journal-title":"BMC Cancer"},{"issue":"10351","key":"10.1016\/j.critrevonc.2024.104307_bib19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0140-6736(22)01390-3","article-title":"Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials","volume":"400","author":"Chihara","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104307_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/djad013","article-title":"Use of artificial intelligence for cancer clinical trial enrollment: a systematic review and meta-analysis","volume":"115","author":"Chow","year":"2023","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2024.104307_bib21","unstructured":"Commissioner of the\u00a0Basics About Clinical Trials, 2022. FDA [cited July 17, 2022]. Available at: \u3008https:\/\/www.fda.gov\/patients\/clinical-trials-what-patients-need-know\/basics-about-clinical-trials\u3009."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104307_bib22","first-page":"90","article-title":"Ethical and practical problems of early anti-cancer drug trials: a review of the literature","volume":"5","author":"Cox","year":"1996","journal-title":"Eur. J. Cancer Care"},{"key":"10.1016\/j.critrevonc.2024.104307_bib23","unstructured":"Dataviz, 2023. CLIP2 INCa [Internet]. [cited May 30, 2023]. Available at: \u3008https:\/\/e-cancer.shinyapps.io\/DATAVIZ_SCREEN\/\u3009."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104307_bib24","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.1995.13.5.1062","article-title":"Perceptions of cancer patients and their physicians involved in phase I trials","volume":"13","author":"Daugherty","year":"1995","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103888","article-title":"Molecular analysis for refractory rare cancers: sequencing battle continues - learnings for the MOSCATO-01 study","volume":"181","author":"Debien","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104307_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/oxfordjournals.annonc.a057716","article-title":"Responses and toxic deaths in phase I clinical trials","volume":"1","author":"Decoster","year":"1990","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib27","first-page":"709","article-title":"Natural Language processing for patient selection in phase I or II Oncology Clinical Trials","volume":"5","author":"Delorme","year":"2021","journal-title":"JCO Clin. Cancer Inf."},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104307_bib28","doi-asserted-by":"crossref","first-page":"00732","DOI":"10.1016\/j.annonc.2023.06.004","article-title":"Searching for clinical trials in oncology: finding a path through the Maze","volume":"7534","author":"Desai","year":"2023","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.06.004","article-title":"Searching for clinical trials in oncology: finding a path through the maze","author":"Desai","year":"2023","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104307_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.39884","article-title":"Participation of patients from racial and ethnic minority groups in phase 1 early cancer drug development trials in the US, 2000-2018","volume":"5","author":"Dunlop","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2024.104307_bib31","unstructured":"Essais Cliniques, 2022. 9\u00e8me enqu\u00eate\u00a0\u201cAttractivit\u00e9 de la France pour la recherche clinique\u201d et sa synth\u00e8se [Internet]. [cited December 21,]. Available at: \u3008https:\/\/www.leem.org\/publication\/essais-cliniques-9eme-enquete-attractivite-de-la-france-pour-la-recherche-clinique-et\u3009."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104307_bib32","first-page":"1105","article-title":"Therapeutic response in phase I trials of antineoplastic agents","volume":"70","author":"Estey","year":"1986","journal-title":"Cancer Treat. Rep."},{"key":"10.1016\/j.critrevonc.2024.104307_bib33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"10.1016\/j.critrevonc.2024.104307_bib34","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jbi.2018.02.019","article-title":"A clinician friendly data warehouse oriented toward narrative reports: Dr. Warehouse","volume":"80","author":"Garcelon","year":"2018","journal-title":"J. Biomed. Inf."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104307_bib35","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/cncr.26413","article-title":"Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center","volume":"118","author":"Garrido-Laguna","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2024.104307_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103860","article-title":"A systematic review of contemporary phase I trials in patients with lymphoma","volume":"180","author":"Griguolo","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmorw.2023.100006","article-title":"Equitable access to oncology clinical trials: harnessing technology to reduce geographic disparities","author":"Hardy-Werbin","year":"2023","journal-title":"ESMO Real World Data Digit. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104307_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12967-022-03432-5","article-title":"Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway","volume":"20","author":"Helland","year":"2022","journal-title":"J. Transl. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104307_bib39","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.bulcan.2016.10.001","article-title":"The ConSoRe project supports the implementation of big data in oncology","volume":"103","author":"Heudel","year":"2016","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104307_bib40","doi-asserted-by":"crossref","first-page":"viii28","DOI":"10.1093\/annonc\/mdy269.090","article-title":"Vall d\u2019Hebron Institute of Oncology (VHIO) immuno-oncology prognostic index (VIO): a new tool for improved patient (pt) selection in phase I (Ph1) trials with immune checkpoint inhibitors (ICI)","volume":"29","author":"Hierro","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib41","unstructured":"Home, 2022. ClinicalTrials.gov [Internet]. [cited December 26, 2022]. Available at: \u3008https:\/\/clinicaltrials.gov\/\u3009."},{"key":"10.1016\/j.critrevonc.2024.104307_bib42","unstructured":"Home, 2023. Cancertrials.be [Internet]. [cited July 20, 2023]. Available at: \u3008https:\/\/www.cancertrials.be\/\u3009."},{"key":"10.1016\/j.critrevonc.2024.104307_bib43","unstructured":"Homepage, 2023. Intelligent Health [Internet]. [cited May 30, 2023]. Available at: \u3008https:\/\/intelligenthealth.ai\/\u3009."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104307_bib44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdy539","article-title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong","year":"2019","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2024.104307_bib45","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C Inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104307_bib46","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMsa042220","article-title":"Risks and benefits of phase 1 oncology trials, 1991 through 2002","volume":"352","author":"Horstmann","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104307_bib47","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMsa042220","article-title":"Risks and benefits of phase 1 oncology trials, 1991 through 2002","volume":"352","author":"Horstmann","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104307_bib48","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdm548","article-title":"Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy","volume":"19","author":"Italiano","year":"2008","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104307_bib49","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1740774514536000","article-title":"Organizational and physician factors associated with patient enrollment in cancer clinical trials","volume":"11","author":"Jacobs","year":"2014","journal-title":"Clin. Trials"},{"key":"10.1016\/j.critrevonc.2024.104307_bib50","unstructured":"Jin, Q., Wang, Z., Floudas, C.S., Sun, J., Lu, Z., 2023. Matching Patients to Clinical Trials with Large Language Models [Internet]. arXiv [cited August 31, 2023]. Available at: \u3008http:\/\/arxiv.org\/abs\/2307.15051\u3009."},{"key":"10.1016\/j.critrevonc.2024.104307_bib51","article-title":"NLI4CT: Multi-evidence natural language inference for clinical trial reports [Internet]","author":"Jullien","year":"2023","journal-title":"arXiv"},{"key":"10.1016\/j.critrevonc.2024.104307_bib52","doi-asserted-by":"crossref","unstructured":"Jullien, M., Valentino, M., Frost, H., O\u2019regan, P., Landers, D., Freitas, A., 2023b. SemEval-2023 Task 7: multi-evidence natural language inference for clinical trial data. In: Proceedings of the 17th International Workshop on Semantic Evaluation (SemEval-2023) Toronto, Canada: Association for Computational Linguistics 2023 [cited September 13, 2023], pp. 2216\u20132226. Available at: \u3008https:\/\/aclanthology.org\/2023.semeval-1.307\u3009.","DOI":"10.18653\/v1\/2023.semeval-1.307"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104307_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154895","article-title":"A case-control study brings to light the causes of screen failures in phase 1 cancer clinical trials","volume":"11","author":"Kempf","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104307_bib54","first-page":"369","article-title":"Using scenarios to explain life expectancy in advanced cancer: attitudes of people with a cancer experience","volume":"21","author":"Kiely","year":"2013","journal-title":"Support Care Cancer J. Multinatl. Assoc. Support Care Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104307_bib55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-022-00312-5","article-title":"MatchMiner: an open-source platform for cancer precision medicine","volume":"6","author":"Klein","year":"2022","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib56","unstructured":"Klineo, 2022. [Internet]. [cited December 26, 2022]. Available at: \u3008https:\/\/www.klineo.fr\/\u3009."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104307_bib57","article-title":"National Center for Tumor Diseases Precision Oncology Thesaurus for Drugs: a curated database for drugs, drug classes, and drug targets in precision cancer medicine","author":"Kreutzfeldt","year":"2023","journal-title":"JCO Clin. Cancer Inf."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104307_bib58","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12885-023-10632-9","article-title":"ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial","volume":"23","author":"Kringelbach","year":"2023","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104307_bib59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.12788\/j.suponc.0004","article-title":"Predicting life expectancy in patients with advanced incurable cancer: a review","volume":"11","author":"Krishnan","year":"2013","journal-title":"J. Support Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib60","unstructured":"Le Plan Cancer, 2023. Le Plan cancer 2014-2019 [Internet]. [cited June 1, 2023]. Available at:\u00a0\u3008https:\/\/www.e-cancer.fr\/Institut-national-du-cancer\/Strategie-de-lutte-contre-les-cancers-en-France\/Les-Plans-cancer\/Le-Plan-cancer-2014-2019\u3009."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104307_bib61","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104307_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007959","article-title":"Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1\/PD-L1 inhibitors","volume":"12","author":"Li","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104307_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1472-6963-9-155","article-title":"What causes increasing and unnecessary use of radiological investigations? A survey of radiologists\u2019 perceptions","volume":"9","author":"Lysdahl","year":"2009","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.critrevonc.2024.104307_bib64","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2021.05.040","article-title":"Phase I prognostic online (PIPO): a web tool to improve patient selection for oncology early phase clinical trials","volume":"155","author":"Matos","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104307_bib65","first-page":"774","article-title":"Determinants of patient screen failures in Phase 1 clinical trials","volume":"31","author":"Mckane","year":"2013","journal-title":"Investig. New\u00a0Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104307_bib66","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1200\/JCO.2012.45.0999","article-title":"Effect of patient socioeconomic status on access to early-phase cancer trials","volume":"31","author":"Mohd Noor","year":"2013","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104307_bib67","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s43018-021-00236-2","article-title":"An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication","volume":"2","author":"Morin","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2024.104307_bib68","unstructured":"NCRI Cancer Conference Abstracts, 2023. Screen failures in Phase I trials - a single institution experience [Internet] [cited May 29, 2023]. Available at:\u00a0\u3008https:\/\/abstracts.ncri.org.uk\/abstract\/screen-failures-in-phase-i-trials-a-single-institution-experience\/\u3009."},{"key":"10.1016\/j.critrevonc.2024.104307_bib69","first-page":"15","article-title":"Increasing the efficiency of trial-patient matching: automated clinical trial eligibility pre-screening for pediatric oncology patients","volume":"14","author":"Ni","year":"2015","journal-title":"BMC Med. Inf. Decis. Mak."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104307_bib70","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cncr.34649","article-title":"MatchMiner open-source platform matches patients with cancer to precision medicine trials","volume":"129","author":"Nierengarten","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2024.104307_bib71","unstructured":"Number of Trial Registrations by Location, Disease, Phase of Development, Age and Sex of Trial Participants (1999-2022), 2023. [Internet] [cited May 29, 2023]. Available at:\u3008https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/monitoring\/number-of-trial-registrations-by-year-location-disease-and-phase-of-development\u3009."},{"key":"10.1016\/j.critrevonc.2024.104307_bib72","unstructured":"Nygren, P., 2023. MEGALiT - a Multicenter, Basket and Umbrella Explorative Trial on the Efficacy and Safety of Molecular Profile Selected Commercially Available Targeted Anti-cancer Drugs in Patients With Advanced Cancers Progressive on Standard Therapy [Internet]. clinicaltrials.gov 2020 Oct [cited May 25, 2023]. Report No.: NCT04185831. Available at: \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04185831\u3009."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104307_bib73","article-title":"Digital ECMT cancer trial matching tool: an open source research application to support oncologists in the identification of precision medicine clinical trials","author":"O\u2019Regan","year":"2023","journal-title":"JCO Clin. Cancer Inf."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104307_bib74","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology\u00a0Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104307_bib75","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1200\/JCO.2010.34.5074","article-title":"Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors","volume":"30","author":"Olmos","year":"2012","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib76","unstructured":"OncoClic [Internet], 2023. [cited May 30, 2023]. Available at: \u3008https:\/\/www.oncoclic.fr\/login\u3009."},{"key":"10.1016\/j.critrevonc.2024.104307_bib77","unstructured":"Open-Sourcing a New Parser to Improve Clinical Trial Participant Recruitment, 2023. [Internet]. [cited June 1, 2023]. Available at:\u00a0\u3008https:\/\/ai.facebook.com\/blog\/open-sourcing-a-new-parser-to-improve-clinical-trial-participant-recruitment\/\u3009."},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104307_bib78","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-human phase I\/IB dose-finding study of Adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2024.104307_bib79","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.e18725","article-title":"A self-assessment survey to identify the risk of screen failure in phase I clinical trials (SCITEP score)","volume":"41","author":"Ouali","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib80","unstructured":"PCM4EU [Internet], 2023. [cited July 31, 2023]. Available at: \u3008https:\/\/health.ec.europa.eu\/non-communicable-diseases\/cancer\/europes-beating-cancer-plan-eu4health-financed-projects\/projects\/pcm4eu_en\u3009."},{"issue":"23","key":"10.1016\/j.critrevonc.2024.104307_bib81","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1002\/cncr.33853","article-title":"Disparities in phase 1 cancer clinical trial enrollment","volume":"127","author":"Perni","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2024.104307_bib82","doi-asserted-by":"crossref","unstructured":"Piat, C., Blampey, Q., Joutard, A., Qabel, M.A., Di Piazza, T., Benassayag, U., , 2023. A Validated and Explainable Deep Learning Model Instantly Predicts Survival from Consultation Reports [Internet]. Rochester, NY [cited May 30, 2023]. Available at:\u00a0\u3008https:\/\/papers.ssrn.com\/abstract=4410792\u3009.","DOI":"10.2139\/ssrn.4410792"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104307_bib83","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/sj.bjc.6605030","article-title":"Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?","volume":"100","author":"Postel-Vinay","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104307_bib84","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/annonc\/mdv550","article-title":"Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies","volume":"27","author":"Postel-Vinay","year":"2016","journal-title":"Ann. Oncol. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib85","unstructured":"PRIME-ROSE, 2023. A European precision cancer medicine trial network and implementation initiative funded by the EU Cancer Mission [Internet]. ReThink Health [cited July 31, 2023]. Available at:\u00a0\u3008https:\/\/rethink-health.eu\/projects\/prime-rose-european-precision-cancer-medicine-trial-network-and-implementation-initiative\/\u3009."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104307_bib86","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/bib\/bby061","article-title":"Recent applications of deep learning and machine intelligence on in silico drug discovery: methods, tools and databases","volume":"20","author":"Rifaioglu","year":"2019","journal-title":"Brief. Bioinform."},{"issue":"17","key":"10.1016\/j.critrevonc.2024.104307_bib87","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1001\/jama.292.17.2130","article-title":"Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials","volume":"292","author":"Roberts","year":"2004","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104307_bib88","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/07357907.2022.2104305","article-title":"Suspension of oncology randomized clinical trials during the COVID-19 pandemic: a cross-sectional evaluation of COVID-related suspensions","volume":"40","author":"Sayyid","year":"2022","journal-title":"Cancer Investig."},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104307_bib89","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2024.104307_bib90","unstructured":"SCREENACT, 2022. La recherche de demain s\u2019invente aujourd\u2019hui [Internet]. SCREENACT [cited December 26,]. Available at:\u00a0\u3008https:\/\/screenact.fr\u3009."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104307_bib91","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/bjc.2017.480","article-title":"Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials","volume":"118","author":"Sen","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104307_bib92","first-page":"3399","article-title":"Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patients","volume":"28","author":"Smith-Uffen","year":"2020","journal-title":"Support Care Cancer J. Multinatl. Assoc. Support Care Cancer"},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104307_bib93","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.22.00537","article-title":"Clinical trial eligibility criteria: a structural barrier to diversity in clinical trial enrollment","volume":"40","author":"Snyder","year":"2022","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104307_bib94","unstructured":"The START Center, 2023. The START Center for Cancer Care in San Antonio, TX [Internet] [cited July 20, 2023]. Available at:\u00a0\u3008https:\/\/www.thestartcenter.com\u3009.."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104307_bib95","first-page":"35","article-title":"Feasibility of cancer clinical trial enrollment goals based on cancer incidence","author":"Tran","year":"2020","journal-title":"JCO Clin. Cancer Inf."},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104307_bib96","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/annonc\/mdz080","article-title":"Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","volume":"30","author":"Tr\u00e9dan","year":"2019","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104307_bib97","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.1235","article-title":"Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials","volume":"1","author":"Unger","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2024.104307_bib98","unstructured":"UpSMART, 2023. [Internet]. [cited May 30, 2023]. Available at:\u00a0https:\/\/upsmart.digitalecmt.com\/."},{"key":"10.1016\/j.critrevonc.2024.104307_bib99","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1093\/annonc\/mdz027.001","article-title":"3O - Applicability of the lung immune prognostic index (LIPI) in patients with metastatic solid tumors when treated with immune checkpoint inhibitors (ICI) in early clinical trials","volume":"30","author":"Varga","year":"2019","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104307_bib100","first-page":"0134","article-title":"Redundant laboratory testing on referral from general practice to the outpatient clinic: a post-hoc analysis","volume":"6","author":"Vrijsen","year":"2021","journal-title":"BJGP Open"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104307_bib101","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-11-2217","article-title":"Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience","volume":"18","author":"Wheler","year":"2012","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104307_bib102","unstructured":"When Offered to Participate, 2023. A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials - PubMed [Internet]. [cited May 29, 2023]. Available at:\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/33022716\/."},{"key":"10.1016\/j.critrevonc.2024.104307_bib103","unstructured":"World Health Organization, 2023. WHO [Internet]. [cited June 1, 2023]. Available at:\u00a0\u3008https:\/\/www.who.int\u3009."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104307_bib104","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/02692163221137105","article-title":"Motivations and experiences of patients with advanced cancer participating in Phase 1 clinical trials: a qualitative study","volume":"37","author":"Yang","year":"2023","journal-title":"Palliat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104307_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41746-022-00742-2","article-title":"A large language model for electronic health records","volume":"5","author":"Yang","year":"2022","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.critrevonc.2024.104307_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2021.103983","article-title":"CODER: Knowledge-infused cross-lingual medical term embedding for term normalization","volume":"126","author":"Yuan","year":"2022","journal-title":"J. Biomed. Inf."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824000507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T16:56:22Z","timestamp":1778518582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824000507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":106,"alternative-id":["S1040842824000507"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104307","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients\u2019 selection and trial matching in early-phase oncology clinical trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104307"}}